Coronavirus Notebook: EU & Australia Assessing Comirnaty In 5-11 Year Olds, Aviptadil Shows Promise In Critical COVID-19 Patients
Executive Summary
The European Medicines Agency has OKd new manufacturing sites and a ready-to-use formulation for Comirnaty, while Australia has provisionally approved Ronapreve for treatment and post-exposure prophylaxis. The UK has secured supplies of two investigational antiviral products from Pfizer and MSD.
You may also be interested in...
Coronavirus Notebook: CEPI Calls For Reduced-Dose Booster Trials, Regeneron’s Ronapreve Filed In EU
EU health ministers are discussing booster and additional vaccines as well as COVID-19-related medicines shortages, and England is to offer approved vaccines to clinical trialists to ease international travel.
Merck’s Molnupiravir Set To Lead Forecast $6bn COVID-19 Oral Antiviral Market
Merck’s antiviral could play a big role, but only if it proves effective in broader settings, such as post-exposure prophylaxis.
Coronavirus Notebook: Nobel Laureates Press Germany To Back Vaccine IP Waiver
The EU vaunts its vaccine donations and starts building resilience against future health threats, and the UK MHRA says Moderna can be used as a booster dose. Aviptadil has received scientific advice from the MHRA for its potential use as a treatment for COVID-19 patients.